MENU Quick Go

  • HOME
  • About PharmAbcine
  • Management

Dr. Jin-San YOO, president and CEO of PharmAbcine, Inc. in South Korea,
founded PharmAbcine in 2008 as a spin-off venture company from KRIBB
(Korea Research Institute of Biosciences and Biotechnology) with initial
funding from Novartis. Before founding PharmAbcine, he served as a head of
"The Therapeutic Antibody Center" at KRIBB and director of Therapeutic
Antibody Division at LG Life Sciences. Dr. YOO studied microbiology and
organic chemistry at Georg-August University Gottingen and received MS
and PhD in the field of molecular cell biology at the Max-Planck-Institute for
Biophysical Chemistry and was acting as HHMI fellow at Stanford University
School of Medicine and as TSRI senior associate at The Scripps Research Institute.
Dr. Sang Hoon Lee is Co-founder and Executive Vice President of PharmAbcine
in Korea. Dr. Lee is responsible for research and development, and supports
strategic management of the company. Prior to PharmAbcine,
Dr. Lee worked at Chiron (Currently Novartis), AstraZeneca R&D Boston, Genentech
and Exelixis in USA and had broad experiences in biotechnology and development
of molecular targeted therapies.
Dr. Lee received B.S. and M.S. at Seoul National University and Ph.D. in Molecular,
Cellular and Development Biology from The Ohio State University.
He had research experiences at Beth Israel Hospital & Harvard Medical School,
UCSF and Stanford Medical School.